2023 has brought with it some big-ticket patent expiries on the Indian market.
Even as twists and turns around the patent battle pertaining to Novartis AG’s heart-failure therapy Entresto (sacubitril/valsartan) continue to play out, frontline Indian companies have hit the market with generic versions of Pfizer Inc.’s blockbuster anticancer Ibrance (palbociclib). (Also see "Pendulum Swings Again: Entresto Patent In India Restored, For Now" - Scrip, 20 January, 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?